SLC5A2 and diabetic kidney disease: In addition to lowering the urinary albumin/creatinine ratio (UACR) [6], SGLT2 inhibitors reduce the risk of the kidney composite, which includes a substantial decrease in renal filtering capacity (doubling of serum creatinine or a sustained 40% decrease in eGFR), renal replacement therapy and renal death, in cardiovascular outcome trials (CVOTs) in individuals with type 2 diabetes [7–9] and in individuals with established diabetic kidney disease (DKD) and macroalbuminuria [10].